Resources
Clinical data
325,000+
total patients treated
97.9%
placement accuracy
0
seeds damaged
11.37%
re-excision rate
99.8%
retrieval rate
This study shows that Magseed is highly effective for marking and selectively removing axillary lymph nodes in breast cancer patients after neoadjuvant chemotherapy.
Hartmann et al (2023)
This Study involved marking lymph nodes for axillary surgery in breast cancer patients, using Magseed. Placement at chemotherapy start significantly improved correct localization, supporting safe, reliable targeted axillary dissection.
Barry et al (2023)
This Study shows Magseed and Magtrace used together for breast cancer localization and sentinel lymph node detection.
Pantiora et al (2023)
This study from MD Anderson Cancer Center demonstrates the efficacy of the Magseed® marker for breast lymph node marking post Neoadjuvant Chemotherapy
Simons et al (2021)
This meta analysis found that Magseed is a non-inferior, reliable and effective radiation-free localisation alternative to WGL, widely accepted by physicians as it decouples radiology and surgery schedules.
Gera et al (2020)
This study was the largest non-radioactive seed series in the world, demonstrating a highly successful Magseed® marker program implementation.
Miller et al (2020)
This prospective single center study from MD Anderson Cancer Center concludes that the Magseed® marker is safe and effective for localisation and excision of non-palpable breast lesions.
Singh et al (2020)
This study from the Royal Marsden Hospital investigates patient and clinician satisfaction and clinical outcomes for Magseed® localization, demonstrating a clinician preference for Magseed® and a reduction in patient anxiety.
Micha et al (2020)
This multi-center concludes that the Magseed® marker is a reliable marker for breast tumors and pathological axillary node localization in breast cancer patients.
Zatecky et al (2020)
This study from Charité hospital in Berlin, Germany concludes that the Magseed® marker is superior to WGL for patient comfort and reduces operative time.
Kühn et al (2020)
This study investigated the feasibility and efficacy of Magseed®, concluding it to be simple to use and that it consents short lumpectomy time, whilst improving the care pathway and organization of both radiological and surgical teams.
Martinez et al (2020)
This study evaluates the early adoption of the Magseed® marker compared to hookwire lesion localisation.
Zacharioudakis et al (2019)
This study shows that the Magseed® marker is a safe, easy technique with a short learning curve, with efficient use of clinical resources.
Thekkinkattil et al (2019)
This study shows that Magseed® marker localization is a safe, nonradioactive way to accurately localize axillary lymph nodes preoperatively.
Greenwood et al (2019)
This study demonstrates accurate lesion localisation and SLN detection with the combined use of the Magseed® marker and Magtrace® lymphatic tracer.
Hersi et al (2019)
This study demonstrates the combined use of the Magseed® marker and Magtrace® lymphatic tracer for lesion localisation and SLNB.
Pohlodek et al (2019)
This study shows that the Magseed® marker can be accurately placed, demonstrates no migration and is detectable in all sizes and depths of breast tissue.
Harvey et al (2018)
This study – featuring 188 patients – shows that Magseed® marker localisation has the potential to replace conventional wire needle localisation.
Lamb et al (2018)
This study demonstrates the benefits of implementing a Magseed® marker program into a large hospital facility.
Chacko et al (2018)
This study from UCSF shows that the Magseed® marker provides an effective means for preoperative localisation of non-palpable breast lesions.
Price et al (2017)
